168 related articles for article (PubMed ID: 12470795)
1. A safer vaccine for Alzheimer's disease?
Sigurdsson EM; Wisniewski T; Frangione B
Neurobiol Aging; 2002; 23(6):1001-8. PubMed ID: 12470795
[TBL] [Abstract][Full Text] [Related]
2. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
3. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA
Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
[TBL] [Abstract][Full Text] [Related]
5. Novel Abeta immunogens: is shorter better?
Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
[TBL] [Abstract][Full Text] [Related]
6. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.
Bowers WJ; Mastrangelo MA; Stanley HA; Casey AE; Milo LJ; Federoff HJ
Neurobiol Aging; 2005 Apr; 26(4):393-407. PubMed ID: 15653168
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
Kim HD; Jin JJ; Maxwell JA; Fukuchi K
Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
[TBL] [Abstract][Full Text] [Related]
8. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
Ghochikyan A
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):128-43. PubMed ID: 19355933
[TBL] [Abstract][Full Text] [Related]
9. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.
Sigurdsson EM; Scholtzova H; Mehta PD; Frangione B; Wisniewski T
Am J Pathol; 2001 Aug; 159(2):439-47. PubMed ID: 11485902
[TBL] [Abstract][Full Text] [Related]
11. Simplified β-amyloid peptides for safer Alzheimer's vaccines development.
Verdoliva A; Rivieccio V; Rossi M
Hum Vaccin; 2010 Nov; 6(11):936-47. PubMed ID: 20980800
[TBL] [Abstract][Full Text] [Related]
12. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant.
Yu YZ; Wang S; Bai JY; Zhao M; Chen A; Wang WB; Chang Q; Liu S; Qiu WY; Pang XB; Xu Q; Sun ZW
Clin Immunol; 2013 Oct; 149(1):11-24. PubMed ID: 23886550
[TBL] [Abstract][Full Text] [Related]
13. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
Leverone JF; Spooner ET; Lehman HK; Clements JD; Lemere CA
Vaccine; 2003 May; 21(17-18):2197-206. PubMed ID: 12706711
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
[TBL] [Abstract][Full Text] [Related]
15. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
16. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
[TBL] [Abstract][Full Text] [Related]
17. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
19. Norovirus P particle-based active Aβ immunotherapy elicits sufficient immunogenicity and improves cognitive capacity in a mouse model of Alzheimer's disease.
Fu L; Li Y; Hu Y; Zheng Y; Yu B; Zhang H; Wu J; Wu H; Yu X; Kong W
Sci Rep; 2017 Jan; 7():41041. PubMed ID: 28106117
[TBL] [Abstract][Full Text] [Related]
20. Vaccination strategies for Alzheimer's disease: A new hope?
Woodhouse A; Dickson TC; Vickers JC
Drugs Aging; 2007; 24(2):107-19. PubMed ID: 17313199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
